Introduction
Inflammatory myofibroblastic tumor (IMFT) is a rare solid tumor. The
prevalence rate is 0.04% to 0.70%, with a higher incidence in children
and young people (1). IMFT was considered a reparative benign
post-inflammatory condition. However, recent studies have indicated that
IMFTs are lesions with intermediary malignant potential due to their
tendency to invade tissues, recur locally, and metastasize to distant
sites (2).
IMFT can present at any age with a preference for children and
adolescents (3). The tumor frequently presents in the abdominopelvic
region, lungs, and retroperitoneum. However, it can involve any site of
the body (4). The clinical presentation depends on the site of
involvement, a palpable abdominal mass being the most frequent physical
finding, and fever being the most common symptom. Given the indolent
course, the tumor is often diagnosed in an advanced stage (3).
We present data on children diagnosed with IMFT, the varied
presentations, challenges during management and follow-up; and the
efficacy of an oral out-patient based combination chemotherapy.